Analysts Set Integra LifeSciences Holdings Corporation (NASDAQ:IART) PT at $14.20

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have received a consensus rating of “Reduce” from the seven research firms that are currently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $14.20.

A number of research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Friday, March 27th. Wells Fargo & Company raised Integra LifeSciences to a “hold” rating in a research note on Wednesday, March 18th. Truist Financial lowered their price objective on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. Citigroup lowered their price objective on Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating for the company in a research note on Wednesday, March 11th. Finally, Argus reissued a “hold” rating on shares of Integra LifeSciences in a research note on Wednesday, April 15th.

Integra LifeSciences Stock Down 4.0%

IART stock opened at $10.32 on Tuesday. The stock’s 50 day simple moving average is $10.20 and its 200 day simple moving average is $11.89. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $17.54. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.46 and a current ratio of 2.54. The company has a market cap of $804.34 million, a P/E ratio of -1.53 and a beta of 1.06.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.04. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The business had revenue of $434.93 million for the quarter, compared to the consensus estimate of $429.62 million. During the same period in the prior year, the business earned $0.97 EPS. The firm’s revenue for the quarter was down 1.7% on a year-over-year basis. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. On average, research analysts expect that Integra LifeSciences will post 2.34 earnings per share for the current fiscal year.

Institutional Trading of Integra LifeSciences

Several institutional investors and hedge funds have recently modified their holdings of IART. Rubric Capital Management LP raised its stake in shares of Integra LifeSciences by 58.4% in the second quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock worth $90,233,000 after purchasing an additional 2,710,262 shares during the last quarter. Paradigm Capital Management Inc. NY raised its stake in shares of Integra LifeSciences by 57.5% in the second quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company’s stock worth $26,767,000 after purchasing an additional 796,300 shares during the last quarter. Invenomic Capital Management LP increased its position in shares of Integra LifeSciences by 78.3% during the fourth quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock valued at $13,115,000 after acquiring an additional 463,729 shares during the last quarter. Kotler Kevin purchased a new stake in shares of Integra LifeSciences during the fourth quarter valued at approximately $5,309,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Integra LifeSciences during the fourth quarter valued at approximately $4,722,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.